Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Merck Consolidates All Rights To Vernakalant By Assuming North American Rights From Astellas

This article was originally published in PharmAsia News

Executive Summary

Merck & Co. is acquiring North American rights to intravenous vernakalant from Astellas Pharma's U.S. subsidiary, Merck announced on July 26. The agreement will consolidate its interest in the cardiovascular drug to include worldwide rights to both the IV and oral formulations

You may also be interested in...



Sanofi Halts Multaq Trial Early Due To Cardiac Events

The Phase IIIb trial was in patients who had had atrial fibrillation for at least six months; an earlier trial in heart failure also was terminated because of increased risk.

Astellas Likely To Cede U.S. Rights to Vernakalant, Cardiome CEO Says

Cardiome Pharma will likely be announcing a change in ownership for the U.S. rights to the I.V. version of its cardiovascular drug vernakalant by the end of the first quarter, CEO Doug Janzen told analysts on an earnings call

Where A REMS Didn't Help: Sanofi Must Deal With Liver Injuries With Multaq

Company has sent a "Dear Dr." letter describing rare cases of liver problems and will also send additional data to FDA from the clinical trials.

Related Content

UsernamePublicRestriction

Register

SC078611

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel